A Phase 3 interventional study of SD-809 and Placebo in Tardive Dyskinesia, sponsored by Auspex Pharmaceuticals, Inc.. Completed at 82 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-01.
Sponsored by Auspex Pharmaceuticals, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.
Among the 31 studies in Tardive Dyskinesia with a site in United States, this one has the largest enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2014, is one of 6 in phase 3, and was the 12th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
Neurocrine Biosciences · Sites in United States, Bulgaria, Puerto Rico
Ages 18–75
Neurocrine Biosciences · Sites in United States
Ages 18+
iRxReminder · Sites in United States
Ages 18+
Corporal Michael J. Crescenz VA Medical Center · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 8
First in 1996; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 89 across the 27 interventional studies, 70 across the 3 observational. Of the 21 that completed or were terminated, 14 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Auspex Pharmaceuticals, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Auspex Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Teva Pharmaceutical Industries, Ltd. has 3 studies filed under Tardive Dyskinesia — fewer than ten, so there is no comparison to draw.
2 of the studies in Tardive Dyskinesia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365462Neurocrine BiosciencesEfficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | 2027-02 |
| NCT06997198University Hospitals Cleveland Medical CenterDeutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Tardive Dyskinesia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.
Participants who complete study SD-809-C-18 (NCT02195700), SD-809-C-23 (NCT02291861), or any other SD-809 study will be enrolled in this study. This study include a screening period (Part A), a titration period (Part A), a long-term treatment period (Part A), a double-blind, randomized withdrawal period (Part B), treatment after completion of the randomized withdrawal period (Part B), and a post-treatment safety follow-up period (Part A and Part B). EU participants who complete Part B will be invited to participate in Part C.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
Drug: SD-809
Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.
Drug: SD-809 · Drug: Placebo
Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.
Drug: SD-809
EU participants who complete Part B and willing to continue in the study will continue treatment with SD-809 for 52 weeks at the dose administered during the 12-week open-label period of Part B.
Drug: SD-809
SD-809 will be administered per dose and schedule specified in the arm.
Also known as: Deutetrabenazine; TEV-50717
Placebo matching to SD-809 will be administered per schedule specified in the arm.
Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal
AEs were analyzed as one group combined for parts A and B per planned analysis. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE=prevents normal daily activities. Drug-related TEAEs: TEAEs with possible, probable, or definite relationship to study drug. Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A treatment-emergent AE was defined as an AE that began after the first administration of study medication or existing AEs that worsened after the first dose of study medication. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to the end of follow-up (4 weeks after the last dose of study drug; mean exposure: up to approximately 866.1 days)
Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video Rating
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
Time frame: Day 1 of Part B, Day 7 of Part B
Part A: Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating
The AIMS is an assessment tool used to detect and follow the severity of tardive dyskinesia (TD) over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
Time frame: Baseline, Week 145
Part A: Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
Time frame: Baseline, Week 158
Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
Time frame: Baseline, Week 145
Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
Time frame: Baseline, Week 158
Part A: Percentage of Participants Who Had a 50% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
Time frame: Baseline to Week 145
Part A: Percentage of Participants Who Had a 70% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
Time frame: Baseline to Week 145
Part A: Change From Baseline in AIMS Items 8, 9, and 10 Score at Week 145, as Assessed by the Site Rating
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. Items 8 to 10 deal with global severity as judged by the examiner, and the participant's awareness of the movements and the distress associated with them. Item 8 (used as an overall severity index indicating severity of abnormal movements) was rated on a 5-point anchored scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Items 9 and 10 (provide additional information with regard to participant's incapacitation due to abnormal movements and participant's awareness of abnormal movements) were rated on a 5-point anchored scale ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Higher scores indicated more severe disease.
Time frame: Baseline, Week 145
Part A: Percentage of Participants Who Were a Treatment Success, Based on the Clinical Global Impression of Change (CGIC)
A treatment success was defined as much or very much improved on the CGIC from baseline of this study. The CGIC is a single-item questionnaire that asks the investigator to assess a participant's TD symptoms at specific visits/weeks after initiating therapy. The CGIC uses a 7-point Likert scale, ranging from -3 to +3 (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = not changed, 1 = minimally improved, 2 = much improved, 3 = very much improved), to assess overall response to therapy.
Time frame: Baseline up to Week 145
Part A: Percentage of Participants Who Were a Treatment Success, Based on the Patient Global Impression of Change (PGIC)
A treatment success was defined as much or very much improved on the PGIC from baseline of this study. The PGIC is single-item questionnaire that asks the participant to assess their TD symptoms at specific visits/weeks after initiating therapy. The PGIC uses a 7-point Likert scale, ranging from -3 to +3 (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = not changed, 1 = minimally improved, 2 = much improved, 3 = very much improved), to assess overall response to therapy.
Time frame: Baseline up to Week 145
Part A: Change From Baseline in Modified CDQ-24 Score at Week 158
The CDQ-24 is a disease-specific quality of life questionnaire developed for use in participants with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ-24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains were evaluated in the mCDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by participants on a scale of 0 = never or no impairment to 4 = always or very severe impairment. Total score ranged from 0 - 96, with higher score indicative of severe impairment.
Time frame: Baseline, Week 158
343 participants who completed previous SD-809 studies, including study SD-809-C-18 (NCT02195700) or SD-809-C-23 (NCT02291861) were enrolled and 337 participants were eligible for analysis. 6 participants were not evaluable and were excluded from the analysis due to site data integrity issues as reported to the United States Food and Drug Administration (US FDA).
| Milestone | SD-809 | Part B: Placebo | Part B: SD-809 | Part C: SD-809 |
|---|---|---|---|---|
| Started | 337 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 337 | 0 | 0 | 0 |
| Intent-to-treat (itt) population | 337 | 0 | 0 | 0 |
| Participants who participated in part a but not in part b | 195 | 0 | 0 | 0 |
| Participants who agreed to continue in part b | 142 | 0 | 0 | 0 |
| Completed | 32 | 0 | 0 | 0 |
| Not completed | 305 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 79 | 0 | 0 | 0 |
| Withdrew: Adverse event | 33 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 24 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 9 | 0 | 0 | 0 |
| Withdrew: Death | 8 | 0 | 0 | 0 |
| Withdrew: Noncompliance with study drug | 3 | 0 | 0 | 0 |
| Withdrew: Other than specified | 5 | 0 | 0 | 0 |
| Withdrew: Study terminated | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 |
| Withdrew: Agreed to continue in part b | 142 | 0 | 0 | 0 |
| Milestone | SD-809 | Part B: Placebo | Part B: SD-809 | Part C: SD-809 |
|---|---|---|---|---|
| Started | 0 | 71 | 71 | 0 |
| Randomized withdrawal mitt population | 0 | 63 | 65 | 0 |
| Completed | 0 | 66 | 68 | 0 |
| Not completed | 0 | 5 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 | 0 |
| Milestone | SD-809 | Part B: Placebo | Part B: SD-809 | Part C: SD-809 |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 80 |
| Completed | 0 | 0 | 0 | 73 |
| Not completed | 0 | 0 | 0 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 2 |
AEs were analyzed as one group combined for parts A and B per planned analysis. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE=prevents normal daily activities. Drug-related TEAEs: TEAEs with possible, probable, or definite relationship to study drug. Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A treatment-emergent AE was defined as an AE that began after the first administration of study medication or existing AEs that worsened after the first dose of study medication. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | SD-809 | Part C: SD-809 |
|---|---|---|
| Any TEAEs | 269 | 23 |
| Serious TEAEs | 68 | 5 |
| Severe TEAEs | 57 | 3 |
| Drug-Related TEAEs | 154 | 3 |
| TEAEs Leading to Withdrawal From Study | 42 | 3 |
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
| units on a scale | Part B: Placebo | Part B: SD-809 |
|---|---|---|
| Pre-withdrawal | 5.7 ± 0.55 | 5.0 ± 0.49 |
| Change at Post-withdrawal | 0.6 ± 0.28 | 0 ± 0.29 |
The AIMS is an assessment tool used to detect and follow the severity of tardive dyskinesia (TD) over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
| units on a scale | Part A: SD-809 |
|---|---|
| Part A: Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating | -6.6 ± 0.37 |
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
| units on a scale | Part A: SD-809 |
|---|---|
| Part A: Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating | -6.3 ± 0.85 |
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
| percent change | Part A: SD-809 |
|---|---|
| Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating | -57.0 ± 2.43 |
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
| percent change | Part A: SD-809 |
|---|---|
| Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating | -54.9 ± 6.76 |
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
| percentage of participants | Part A: SD-809 |
|---|---|
| Part A: Percentage of Participants Who Had a 50% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating | 67 |
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. A total motor score from Items 1 to 7 (orofacial, extremity, and truncal movements) was calculated. Items 1 through 7 included facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). Each item was rated on a 5-point anchored scale ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Total motor AIMS score for Items 1-7 ranged from 0 to 28, with higher scores indicative of more severe dyskinesia.
| percentage of participants | Part A: SD-809 |
|---|---|
| Part A: Percentage of Participants Who Had a 70% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating | 42 |
The AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and -scored items. Items 8 to 10 deal with global severity as judged by the examiner, and the participant's awareness of the movements and the distress associated with them. Item 8 (used as an overall severity index indicating severity of abnormal movements) was rated on a 5-point anchored scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Items 9 and 10 (provide additional information with regard to participant's incapacitation due to abnormal movements and participant's awareness of abnormal movements) were rated on a 5-point anchored scale ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Higher scores indicated more severe disease.
| units on a scale | Part A: SD-809 |
|---|---|
| Severity of abnormal movements | -1.3 ± 0.07 |
| Incapacitation due to abnormal movements | -1.3 ± 0.08 |
| Participant's awareness of abnormal movements | -1.3 ± 0.09 |
A treatment success was defined as much or very much improved on the CGIC from baseline of this study. The CGIC is a single-item questionnaire that asks the investigator to assess a participant's TD symptoms at specific visits/weeks after initiating therapy. The CGIC uses a 7-point Likert scale, ranging from -3 to +3 (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = not changed, 1 = minimally improved, 2 = much improved, 3 = very much improved), to assess overall response to therapy.
| percentage of participants | Part A: SD-809 |
|---|---|
| Part A: Percentage of Participants Who Were a Treatment Success, Based on the Clinical Global Impression of Change (CGIC) | 73 |
A treatment success was defined as much or very much improved on the PGIC from baseline of this study. The PGIC is single-item questionnaire that asks the participant to assess their TD symptoms at specific visits/weeks after initiating therapy. The PGIC uses a 7-point Likert scale, ranging from -3 to +3 (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = not changed, 1 = minimally improved, 2 = much improved, 3 = very much improved), to assess overall response to therapy.
| percentage of participants | Part A: SD-809 |
|---|---|
| Part A: Percentage of Participants Who Were a Treatment Success, Based on the Patient Global Impression of Change (PGIC) | 63 |
The CDQ-24 is a disease-specific quality of life questionnaire developed for use in participants with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ-24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains were evaluated in the mCDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by participants on a scale of 0 = never or no impairment to 4 = always or very severe impairment. Total score ranged from 0 - 96, with higher score indicative of severe impairment.
| units on a scale | Part A: SD-809 |
|---|---|
| Part A: Change From Baseline in Modified CDQ-24 Score at Week 158 | -6.3 ± 2.61 |
Collected over Baseline up to the end of follow-up (4 weeks after the last dose of study drug; mean exposure: up to approximately 866.1 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A and Part B Participants | 8/337 (2.4%) | 68/337 (20.2%) | 172/337 (51%) |
| Part C: SD-809 | 2/80 (2.5%) | 5/80 (6.3%) | 5/80 (6.3%) |
| Event | Part A and Part B Participants | Part C: SD-809 |
|---|---|---|
| SchizophreniaPsychiatric disorders | 5/337 | 0/80 |
| Cardiac failureCardiac disorders | 2/337 | 1/80 |
| PneumoniaInfections and infestations | 4/337 | 1/80 |
| DehydrationMetabolism and nutrition disorders | 1/337 | 1/80 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/337 | 1/80 |
| Acute myocardial infarctionCardiac disorders | 0/337 | 1/80 |
| Schizophrenia, paranoid typePsychiatric disorders | 0/337 | 1/80 |
| Circulatory collapseVascular disorders | 0/337 | 1/80 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 4/337 | 0/80 |
| Suicidal ideationPsychiatric disorders | 3/337 | 0/80 |
| Event | Part A and Part B Participants | Part C: SD-809 |
|---|---|---|
| AnxietyPsychiatric disorders | 41/337 | 0/80 |
| DepressionPsychiatric disorders | 35/337 | 0/80 |
| SomnolenceNervous system disorders | 34/337 | 0/80 |
| Weight decreasedInvestigations | 32/337 | 0/80 |
| Urinary tract infectionInfections and infestations | 31/337 | 0/80 |
| DiarrhoeaGastrointestinal disorders | 27/337 | 0/80 |
| HeadacheNervous system disorders | 24/337 | 0/80 |
| HypertensionVascular disorders | 23/337 | 1/80 |
| DyskinesiaNervous system disorders | 22/337 | 2/80 |
| NasopharyngitisInfections and infestations | 20/337 | 2/80 |
ITT population included all participants who were enrolled in the study, regardless of whether or not a participant received a dose of study drug.
| Age, Continuous(years) | SD-809 |
|---|---|
| Mean | 56.9 ± 10.65 |
| Sex: Female, Male(Participants) | SD-809 |
|---|---|
| Female | 188 |
| Male | 149 |
| Ethnicity (NIH/OMB)(Participants) | SD-809 |
|---|---|
| Hispanic or Latino | 28 |
| Not Hispanic or Latino | 300 |
| Unknown or Not Reported | 9 |
| Race/Ethnicity, Customized(Participants) | SD-809 |
|---|---|
| Race — American Indian or Alaskan Native | 1 |
| Race — Asian | 2 |
| Race — Black | 69 |
| Race — White | 264 |
| Race — Other | 1 |
| Total Motor Abnormal Involuntary Movement Scale (AIMS) Score(units on a scale) | SD-809 |
|---|---|
| Mean | 10.7 ± 4.68 |
| AIMS Individual Items (8-10) Scores(units on a scale) | SD-809 |
|---|---|
| Severity of abnormal movements | 2.6 ± 0.78 |
| Incapacitation due to abnormal movements | 2.0 ± 1.07 |
| Participant's awareness of abnormal movements | 2.2 ± 1.08 |
| Modified Craniocervical Dystonia Questionnaire 24 (CDQ-24) Score(units on a scale) | SD-809 |
|---|---|
| Mean | 29.2 ± 18.96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)
Ran from Oct 2014 to primary completion in Dec 2019, 61 months.
Results were first posted in Mar 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deutetrabenazine
Auspex Pharmaceuticals, Inc. →